Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study

Summit Therapeutics, AstraZeneca, and Daiichi Sankyo have announced a clinical trial collaboration to evaluate Ivonescimab in combination with the TROP2-directed ADC Datroway across multiple tumor types. The collaboration will commence with a Phase III study focusing on first-line treatment for triple-negative breast cancer.